Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Detroit, Michigan

Phase 1 cancer trials in Detroit, MI

55 Phase 1 cancer studies are recruiting participants at sites in Detroit as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Detroit at a glance

Breast cancer studies recruiting in Detroit

Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Henry Ford Cancer Institute
    Registry record
    NCT06253871 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Barbara Ann Karmanos Cancer Center
    Registry record
    NCT07488676 · updated
  3. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    Brigitte Harris Cancer Pavilion BHCP · Karmanos Cancer Institute
    Registry record
    NCT06827236 · updated
  4. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT07503808 · updated
  5. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT05579366 · updated
  6. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Barbara Ann Karmanos Cancer Institute
    Registry record
    NCT07114601 · updated
  7. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Barbara Ann Karmanos Cancer Institute
    Registry record
    NCT07213791 · updated
  8. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Aminex Therapeutics, Inc.
    Study site
    Wayne State University - Barbara Ann Karmanos Cancer Institute
    Registry record
    NCT07287917 · updated
  9. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Karmanos Cancer Institiute
    Registry record
    NCT06293898 · updated
  10. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Accent Therapeutics
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT06799065 · updated
  11. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Henry Ford Hospital
    Registry record
    NCT05386108 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Detroit

  1. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Henry Ford Health System
    Registry record
    NCT07111520 · updated
  2. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Henry Ford Cancer Institute
    Registry record
    NCT04198766 · updated
  3. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Henry Ford Health
    Registry record
    NCT06706076 · updated
  4. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    Henry Ford Cancer Institute
    Registry record
    NCT05856981 · updated
  5. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT07542704 · updated
  6. Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Henry Ford Hospital - Detroit /ID# 271642
    Registry record
    NCT06772623 · updated
  7. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    DualityBio Inc.
    Registry record
    NCT05914116 · updated
  8. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Frontier Medicines Corporation
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT06244771 · updated
  9. A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Zai Lab (Shanghai) Co., Ltd.
    Study site
    Barbara Ann Karmanos Cancer Institute
    Registry record
    NCT06179069 · updated
  10. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    Henry Ford Health System
    Registry record
    NCT06026410 · updated
  11. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Brigitte Harris Cancer Pavilion BHCP
    Registry record
    NCT07070232 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Detroit

  1. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Henry Ford Health
    Registry record
    NCT03972657 · updated
  2. Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 to 130
    • Male participants
    Sponsor
    AstraZeneca
    Registry record
    NCT07181161 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Detroit

  1. A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Outpace Bio, Inc.
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT07664735 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Detroit, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Detroit

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's Hospital of Michigan
    Registry record
    NCT04726241 · updated
  2. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    Henry Ford Cancer Institute
    Registry record
    NCT05384626 · updated
  3. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SciTech Development, Inc.
    Study site
    Barbara Ann Karmanos Cancer Institute Wayne State University
    Registry record
    NCT04234048 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Detroit, MI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Detroit

  1. A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT07186842 · updated
  2. PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    PanTher Therapeutics
    Study sites
    Henry Ford Health System · Karmanos Cancer Institute
    Registry record
    NCT06673017 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Ask about studies near Detroit

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call